Spots Global Cancer Trial Database for malignant solid tumor
Every month we try and update this database with for malignant solid tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors | NCT06057038 | Malignant Solid... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-Fluorouracil | 18 Years - | Genmab | |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | NCT01846429 | Tumor Cancer Pain Malignant Solid... Unresectable Ma... Hematologic Mal... Multiple Myelom... Lymphoma Neoplasm Metast... | Sodium Bicarbon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. | NCT03553108 | Malignant Solid... | Olaparib Treatm... Olaparib Treatm... Olaparib Treatm... Olaparib Treatm... | 18 Years - 130 Years | AstraZeneca | |
| A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | NCT00452413 | Non-Small Cell ... Malignant Solid... | enzastaurin erlotinib | 18 Years - | Eli Lilly and Company | |
| Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | NCT03694249 | Malignant Solid... | Ifetroban Sodiu... Placebo | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors | NCT05141474 | Epithelial Tumo... Malignant Solid... | NEXTGEN-TIL Non-myeloablati... Interleukin-2 | 18 Years - | Vall d'Hebron Institute of Oncology | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors | NCT06057038 | Malignant Solid... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-Fluorouracil | 18 Years - | Genmab | |
| CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) | NCT04151342 | Cancer Malignancies Mu... Malignant Solid... Cancer, Therapy... Molecular Seque... Genetic Alterat... Gene Fusion Receptor Tyrosi... RTK Family Gene... Ras (Kras or Nr... | Cancer treatmen... Patient-reporte... | 18 Years - | University Health Network, Toronto | |
| A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | NCT01648764 | Malignant Solid... Solid Tumor Metastatic Tumo... | LY2334737 | 18 Years - | Eli Lilly and Company | |
| A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 | NCT02096341 | Malignant Solid... Lymphomas | RRx-001 | 18 Years - | EpicentRx, Inc. | |
| Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | NCT03694249 | Malignant Solid... | Ifetroban Sodiu... Placebo | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies | NCT03834662 | Malignant Solid... | AVID200 | 18 Years - | Formation Biologics | |
| A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | NCT00452413 | Non-Small Cell ... Malignant Solid... | enzastaurin erlotinib | 18 Years - | Eli Lilly and Company | |
| A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors | NCT06057038 | Malignant Solid... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-Fluorouracil | 18 Years - | Genmab | |
| A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors | NCT03192345 | Malignant Solid... | SAR439459 Cemiplimab REGN... | 18 Years - | Sanofi | |
| Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors | NCT01670175 | Malignant Solid... Childhood Solid... | Sirolimus, Cycl... | - 25 Years | University of California, San Francisco | |
| Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services | NCT03905720 | Malignant Solid... Pain | Acupuncture Pain Counseling | 21 Years - | University of California, San Francisco | |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | NCT04145622 | Advanced Solid ... Malignant Solid... | Ifinatamab deru... | 18 Years - | Daiichi Sankyo | |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | NCT01846429 | Tumor Cancer Pain Malignant Solid... Unresectable Ma... Hematologic Mal... Multiple Myelom... Lymphoma Neoplasm Metast... | Sodium Bicarbon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | NCT06391775 | Malignant Solid... | GEN1055 Pembrolizumab Standard Chemot... | 18 Years - | Genmab | |
| A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | NCT01648764 | Malignant Solid... Solid Tumor Metastatic Tumo... | LY2334737 | 18 Years - | Eli Lilly and Company | |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | NCT04145622 | Advanced Solid ... Malignant Solid... | Ifinatamab deru... | 18 Years - | Daiichi Sankyo | |
| A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors | NCT04571892 | Malignant Solid... | Super circulati... | 18 Years - 75 Years | Shanghai East Hospital | |
| Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | NCT01639911 | Malignant Neopl... CNS Malignancy Malignant Neopl... Genitourinary N... Head and Neck N... Melanoma Malignant Neopl... | Alisertib Pazopanib | 18 Years - | University of Illinois at Chicago | |
| Targeted T-cell Therapy in Solid Tumors | NCT04076137 | Malignant Solid... | Targeted T-cell... | 18 Years - 75 Years | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. | |
| Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | NCT05727839 | Cutaneous Tumor Malignant Solid... | JCXH-211 Inject... | 18 Years - 75 Years | Immorna Biotherapeutics, Inc. | |
| A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors | NCT04632108 | Malignant Solid... | ASKB589 Injecti... | 18 Years - 75 Years | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | |
| Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor | NCT03551795 | Malignant Solid... | Infusion of iNK... | 18 Years - 65 Years | Shanghai Public Health Clinical Center | |
| An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab | NCT02754141 | Malignant Solid... | BMS-986179 Nivolumab rHuPH20 | 18 Years - | Bristol-Myers Squibb | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | NCT05727839 | Cutaneous Tumor Malignant Solid... | JCXH-211 Inject... | 18 Years - 75 Years | Immorna Biotherapeutics, Inc. | |
| ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan | NCT00836888 | Malignant Solid... | ONO-4538 | 20 Years - | Ono Pharmaceutical Co. Ltd | |
| Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | NCT01023737 | Malignant Solid... | Hydroxychloroqu... Vorinostat | 16 Years - | The University of Texas Health Science Center at San Antonio | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | NCT06391775 | Malignant Solid... | GEN1055 Pembrolizumab Standard Chemot... | 18 Years - | Genmab | |
| A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab | NCT02518958 | Malignant Solid... Lymphoma | RRx-001 Nivolumab | 18 Years - | EpicentRx, Inc. | |
| RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) | NCT02801097 | Malignant Solid... Metastatic Canc... Advanced Cancer | RRx-001 Irinotecan | 18 Years - | EpicentRx, Inc. | |
| Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | NCT00395434 | Tumors | Combretastatin ... Bevacizumab (Av... | 18 Years - | Mateon Therapeutics | |
| Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation | NCT02844400 | Malignant Solid... Hematologic Mal... | Biometric Devic... Physical Perfor... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | NCT05468359 | Refractory Soli... Hepatocellular ... Malignant Solid... Pediatric Cance... Pediatric Solid... Fibrolamellar C... | Atezolizumab Sorafenib Bevacizumab Cyclophosphamid... | - 30 Years | St. Jude Children's Research Hospital | |
| Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | NCT01023737 | Malignant Solid... | Hydroxychloroqu... Vorinostat | 16 Years - | The University of Texas Health Science Center at San Antonio | |
| Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor | NCT03551795 | Malignant Solid... | Infusion of iNK... | 18 Years - 65 Years | Shanghai Public Health Clinical Center | |
| Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | NCT05539157 | Cutaneous Tumor Malignant Solid... | JCXH-211 | 18 Years - 75 Years | Immorna Biotherapeutics, Inc. | |
| A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies | NCT03834662 | Malignant Solid... | AVID200 | 18 Years - | Formation Biologics | |
| Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors | NCT01670175 | Malignant Solid... Childhood Solid... | Sirolimus, Cycl... | - 25 Years | University of California, San Francisco | |
| Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects | NCT01359982 | Malignant Solid... Lymphomas | RRx-001 RRx-001 RRx-001 RRx-001 RRx-001 RRx-001 | 18 Years - | EpicentRx, Inc. | |
| A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors | NCT04571892 | Malignant Solid... | Super circulati... | 18 Years - 75 Years | Shanghai East Hospital | |
| An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab | NCT02754141 | Malignant Solid... | BMS-986179 Nivolumab rHuPH20 | 18 Years - | Bristol-Myers Squibb | |
| A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors | NCT01515306 | Malignant Solid... | ramucirumab (IM... paclitaxel | 18 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
